Published in Blood Weekly, November 1st, 2001
"Although high-dose chemotherapy supported by autologous peripheral-blood progenitor-cell (PBPC) transplantation improves response rates and survival for patients with multiple myeloma, all patients eventually develop progressive disease after transplantation," explained A. Keith Stewart, Princess Margaret Hospital in Toronto, colleagues at several U.S. instuitions, and CellPro, Inc., Bothell, Washington, in a multicenter study.
While some researchers...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.